Congress Has Months to Get on the Same Page About TSCA, Experts Say

Why It Matters

The outcome will dictate how quickly new chemicals can reach U.S. markets and the level of health‑protective oversight, directly impacting industry costs and public safety.

Key Takeaways

• TSCA service fee fund expires Sept 30, needing congressional renewal
• House draft would strip citizen petition rights under TSCA section 21
• Senate draft aims to tier reviews, speeding approvals for critical chemicals
• Industry argues EPA review delays exceed 90‑day statutory timeline
• Funding cuts risk weakening EPA’s capacity to assess chemical risks

Pulse Analysis

The Toxic Substances Control Act, revamped by the 2016 Lautenberg amendment, introduced a fee‑based mechanism to fund EPA’s chemical‑review program. By charging manufacturers, petroleum and coal producers, the TSCA service‑fee fund was intended to cover the costs of pre‑manufacturing notices and ensure timely risk assessments. With the fund slated to expire on Sept. 30, lawmakers face a narrow window to either renew the fee authority or overhaul the financing structure, a decision that will reverberate across the chemical supply chain.

In Washington, the House and Senate have each released discussion drafts that diverge sharply on how to reshape TSCA. The House proposal tightens definitions, revises EPA’s testing methodology, and controversially strips citizens of their Section 21 petition rights, potentially curbing public participation in chemical oversight. Conversely, the Senate draft focuses on creating tiered review pathways, aiming to speed approvals for high‑value or critical substances while preserving a baseline of safety scrutiny. Industry groups, including the American Chemistry Council, warn that delayed reviews already exceed the 90‑day statutory deadline and that any dilution of EPA’s data‑request authority could leave hazardous chemicals unchecked.

For manufacturers, the legislative limbo translates into strategic uncertainty. Companies must mobilize through trade associations, lobby for funding that sustains robust EPA staffing, and articulate concrete reform priorities to congressional staff. Simultaneously, they should engage customers and employees to build a coalition opposing any weakening of health protections. The eventual shape of TSCA will influence R&D pipelines, compliance costs, and the competitive positioning of U.S. chemicals in the global market, making the next few months critical for both industry and public health advocates.